<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03977896</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL18_0867</org_study_id>
    <nct_id>NCT03977896</nct_id>
  </id_info>
  <brief_title>Feasibility of 11C-MET PET/MRI Imaging in Pediatric Brain Fossa Tumors</brief_title>
  <acronym>TI-TFCE</acronym>
  <official_title>Pilot Study to Evaluate the Feasibility of Hybrid Brain Imaging 11C-MET PET/MRI of Posterior Brain Fossa Tumors in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brain tumors are the most common solid tumors in children and are the second most common&#xD;
      cause of cancer-related death among this population. Posterior brain fossa tumors represent&#xD;
      about 50% of children brain tumors.&#xD;
&#xD;
      Recently, knowledge in molecular biology has permitted to identify different tumors subgroups&#xD;
      of very different prognosis. Today, surgery removal of the tumor is the mandatory.&#xD;
      Neuro-oncological treatment differs depending on the histological and molecular subgroup.&#xD;
      With classical Magnetic Resonance Imaging (cMRI), distinction between different types of&#xD;
      posterior fossa tumors remains difficult.&#xD;
&#xD;
      Positron Emission Tomography combined with MRI (PET/MRI) has proven its benefits for the&#xD;
      management of brain tumors. The direct spatiotemporal correlation makes possible the&#xD;
      assessment of metabolic, anatomical and functional information. PET/MRI would provide&#xD;
      precisions on the pre-therapeutic characterization of tumors, which could permit to modify&#xD;
      the patients' care.&#xD;
&#xD;
      L- [methyl-11C] methionine (11C-MET) is currently the gold-standard tracer used in&#xD;
      neuro-oncology, but few data exists in children. 11C-MET PET/MRI assessment seems promising,&#xD;
      but has not been studied enough. To the best of our knowledge, there is no specific study on&#xD;
      primary brain tumors of the posterior fossa in children using 11C-MET PET/MRI.&#xD;
&#xD;
      The primary objectives of this first pilot study is to evaluate the practical feasibility of&#xD;
      11C-MET PET/MRI imaging (machine accessibility and imaging interpretability) before surgery&#xD;
      in a population of children older than 5 years old with posterior fossa tumors.&#xD;
&#xD;
      The secondary objectives aim to describe :&#xD;
&#xD;
        -  the PET/MRI parameters of the different tumors studied,&#xD;
&#xD;
        -  and the patient's participation acceptation.&#xD;
&#xD;
      This feasibility study will allow us to standardize the PET/MRI measurements; this could&#xD;
      allow us to discriminate, in a larger study, the different tumor subgroups before surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 3, 2019</start_date>
  <completion_date type="Anticipated">May 18, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 18, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients who performed the PET/MRI</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>number of patients called in for PET/MRI who have not realized the PET/MRI</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>number of patients with good quality of the imaging</measure>
    <time_frame>7 days</time_frame>
    <description>The interpretability of the imaging will be evaluated by a Review Committee (two pairs composed each by a radiologist (for MRI imaging) and a nuclear physician (for PET imaging)). The imaging will be classified under good or bad quality</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Posterior Brain Fossa Tumors in Children</condition>
  <arm_group>
    <arm_group_label>11C-MET PET/MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>11C-MET PET/MRI</intervention_name>
    <description>Except PET/MRI imaging, all the examinations will be done according to the patient's usual care.&#xD;
PET/MRI imaging will be realized within max 7 days after children enrollment, and the surgery (usual care) will be performed within max 4 days after PET/MRI imaging.&#xD;
PET/MRI imaging will include the following sequences: T1axial, Diffusion, Magnetic susceptibility post-Gadolinium injection, 3DT1 pre and post-Gadolinium injection, and Arterial Spin Labelling Imaging (ASL).</description>
    <arm_group_label>11C-MET PET/MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥ 5 years old and &lt; 18 years old at enrollment,&#xD;
&#xD;
          -  with primary posterior brain fossa tumor, metastatic or not,&#xD;
&#xD;
          -  hospitalized in the Department of Pediatric Neurosurgery of Femme-Mère-Enfant&#xD;
             Hospital, and for whom a surgery is scheduled,&#xD;
&#xD;
          -  covered by national health insurance,&#xD;
&#xD;
          -  patient's parents or legal guardians who have provided written informed consent prior&#xD;
             to participation in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with contraindication for MRI (claustrophobia, carrying metallic object)&#xD;
&#xD;
          -  Patients with contraindication for Gadolinium injection (including pregnancy and&#xD;
             breastfeeding)&#xD;
&#xD;
          -  patient with recurring posterior brain fossa tumor&#xD;
&#xD;
          -  patient with brain stem infiltrative tumor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre-Aurélien BEURIAT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre-Aurélien BEURIAT, MD</last_name>
    <phone>4 27 85 62 20</phone>
    <phone_ext>+33</phone_ext>
    <email>pierre-aurélien.beuriat@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valérie LAUDY</last_name>
    <email>valerie.laudy@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospices Civils de Lyon - Groupement Hospitalier Est - Hôpital Femme Mère Enfant - Service de Neurochirurgie Pédiatrique</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Aurélien BEURIAT</last_name>
      <email>pierre-aurélien.beuriat@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre-Aurélien BEURIAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 5, 2019</study_first_submitted>
  <study_first_submitted_qc>June 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2019</study_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PET/MRI</keyword>
  <keyword>11C-MET</keyword>
  <keyword>posterior brain fossa tumors</keyword>
  <keyword>children</keyword>
  <keyword>surgery</keyword>
  <keyword>feasibility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carbon-11 methionine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

